Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Agile Therapeutics Debt to Equity Ratio 2013-2023 | AGRX

Current and historical debt to equity ratio values for Agile Therapeutics (AGRX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Agile Therapeutics debt/equity for the three months ending September 30, 2023 was 0.00.
  
Agile Therapeutics Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2023-09-30 $0.02B $-0.01B -1.88
2023-06-30 $0.03B $-0.01B -2.04
2023-03-31 $0.02B $-0.01B -2.45
2022-12-31 $0.02B $-0.01B -3.57
2022-09-30 $0.01B $0.01B 1.95
2022-06-30 $0.03B $0.00B 8.60
2022-03-31 $0.03B $0.00B 9.68
2021-12-31 $0.04B $0.00B 9.05
2021-09-30 $0.03B $0.01B 2.44
2021-06-30 $0.03B $0.03B 1.12
2021-03-31 $0.02B $0.04B 0.70
2020-12-31 $0.02B $0.05B 0.48
2020-09-30 $0.02B $0.07B 0.35
2020-06-30 $0.02B $0.08B 0.28
2020-03-31 $0.02B $0.09B 0.20
2019-12-31 $0.00B $0.05B 0.08
2019-09-30 $0.00B $0.03B 0.06
2019-06-30 $0.00B $0.02B 0.08
2019-03-31 $0.00B $0.03B 0.06
2018-12-31 $0.00B $0.02B 0.11
2018-09-30 $0.01B $0.02B 0.36
2018-06-30 $0.01B $0.03B 0.39
2018-03-31 $0.01B $0.03B 0.40
2017-12-31 $0.01B $0.04B 0.39
2017-09-30 $0.02B $0.04B 0.41
2017-06-30 $0.02B $0.03B 0.62
2017-03-31 $0.02B $0.04B 0.59
2016-12-31 $0.02B $0.04B 0.51
2016-09-30 $0.02B $0.05B 0.44
2016-06-30 $0.02B $0.05B 0.38
2016-03-31 $0.02B $0.06B 0.33
2015-12-31 $0.02B $0.03B 0.70
2015-09-30 $0.02B $0.03B 0.68
2015-06-30 $0.02B $0.04B 0.50
2015-03-31 $0.02B $0.05B 0.41
2014-12-31 $0.02B $0.04B 0.52
2014-09-30 $0.02B $0.04B 0.44
2014-06-30 $0.02B $0.05B 0.37
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B $0.00B 0.00
2013-06-30 $0.00B $0.00B 0.00
2012-12-31 $0.09B $-0.06B -1.47
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.003B $0.020B
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.832B 5.36
Dr Reddy's Laboratories (RDY) India $11.868B 18.76
Aspen Pharmacare (APNHY) South Africa $5.172B 0.00
BridgeBio Pharma (BBIO) United States $4.531B 0.00
Bausch Health Cos (BHC) Canada $3.154B 2.46
Amphastar Pharmaceuticals (AMPH) United States $1.993B 13.64
Supernus Pharmaceuticals (SUPN) United States $1.642B 0.00
Taysha Gene Therapies (TSHA) United States $0.497B 0.00
Generation Bio (GBIO) United States $0.246B 0.00
Assembly Biosciences (ASMB) United States $0.082B 0.00
Personalis (PSNL) United States $0.064B 0.00
Acasti Pharma (ACST) Canada $0.032B 0.00
Sol-Gel Technologies (SLGL) Israel $0.024B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00